Pivotal Acquisition Corp. (PVT.U), is now expected to price their $200 million SPAC tonight, rather than tomorrow, January 31st. The delaying amendments have created all sorts of confusion regarding getting effective in 20 days, but it turns out that it’s NOT 20 days starting the day after you file, but rather, you need to include the actual day you file without the delaying amendment. This means that Pivotal, which we expected to get effective on January 31st (20 days after their most recent amendment filed January 11th), is actually effective as of today, January 30th.
The tip off to pricing was Pivotal filing both their CERT and 8-a12b this morning, indicating an IPO is imminent. However, we now have confirmation that yes, that is in fact, the case – Pivotal is indeed pricing tonight. This means SPACs will be able to get two deals on the board for January – Andina III and now Pivotal – in a market where there are no other IPOs (traditional) getting done for the month. Plus, we have Gores Metropoulos expected to price $375 million tomorrow, but that IPO will count for February.
Next week, we can expect Wealthbridge, RMG, Monocle and maybe even DiamondPeak to IPO, however, stay tuned for any changes in anticipated pricing schedules for those four.
Summary of terms below:
Cantor Fitzgerald is sole book-running manager, BTIG is lead manager.
Graubard Miller and Ellenoff Grossman & Schole LLP, are Issuer’s Counsel and Underwriter’s Counsel, respectively.
Blue Ocean (NASDAQ:BOCN) provided significantly more texture today in the presentation for its $275 million combination with Asian digital media group TNL Mediagene, which it expects to hit profitability in the second half of the year despite a slight shakeup in financing for the transaction. The first big update in the first investor deck is...
At the SPAC of Dawn A brand new market may have just opened up for space de-SPACs as NASA administrator Bill Nelson announced a shift in the agency’s $11 billion program for a mission to return samples from Mars. Rather than rely on the agency’s internal technologies that would be predicted to get a sample...
Overall deal flow between SPACs and biotech firms has slowed over the last year, but some pending FDA changes could breathe new life into particular business models within the space. In particular, the FDA has asked Congress as part of its 2025 Legislative Proposals to eliminate the interchangeability designation for biosimilar medications, claiming the existing...
At the SPAC of Dawn Ever since Digital World announced its combination with Trump Media (NASDAQ:DJT) back in October 2021, it was clear that SPACworld and the Trump show were set to be intertwined for quite some time. And, although not every headline has a bearing on the wider SPAC world, Trump Media’s post-close rise...
AltC (NYSE:ALCC) has reportedly been taking the pitch deck for its combination with nuclear fission firm Oklo on the road in recent weeks, which has generated the rare result of a SPAC trading significantly above its trust value still well before completing its deal. The SPAC has an estimated $10.59 per share in its trust...